Kirsten F, Atkinson K H, Coppleson J V, Elliott P M, Green D, Houghton R, Murray J C, Russell P, Solomon H J, Friedlander M
Br J Obstet Gynaecol. 1987 Jun;94(6):583-8. doi: 10.1111/j.1471-0528.1987.tb03154.x.
Forty-seven patients with locally advanced cervical cancer at high risk of relapse received three cycles of chemotherapy with PVB (cisplatin, vinblastine and bleomycin) before definitive local treatment with either radical surgery or radiotherapy. Thirty-one of the 47 patients (66%) responded to initial chemotherapy, and 11 of them have relapsed compared with 13 of the 16 non-responders. Median time to recurrence was 31 weeks for PVB non-responders but has not yet been reached for PVB responders. After a median follow-up of 128 weeks, 14 of the 31 responders (45%) are alive and disease free compared with 3 of the 16 non-responders (19%). There was a positive correlation between response to chemotherapy and subsequent response to radiotherapy. PVB was in general well tolerated although one death is probably attributable to chemotherapy. A randomized study comparing radiotherapy alone with initial PVB chemotherapy followed by radiotherapy is in progress.
47例具有高复发风险的局部晚期宫颈癌患者在接受根治性手术或放疗等确定性局部治疗前，接受了3个周期的PVB（顺铂、长春花碱和博来霉素）化疗。47例患者中有31例（66%）对初始化疗有反应，其中11例复发，而16例无反应者中有13例复发。PVB无反应者的中位复发时间为31周，而PVB有反应者尚未达到该时间。中位随访128周后，31例有反应者中有14例（45%）存活且无疾病，而16例无反应者中有3例（19%）存活且无疾病。化疗反应与随后的放疗反应之间存在正相关。PVB总体耐受性良好，尽管有1例死亡可能归因于化疗。一项比较单纯放疗与初始PVB化疗后放疗的随机研究正在进行中。
